Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2014 | Research

RETRACTED ARTICLE: The effects of dexamethasone on the proliferation and apoptosis of human ovarian cancer cells induced by paclitaxel

Authors: Wenjing Hou, Jianhua Guan, Huan Lu, Qian Dong, Yuhong Han, Rong Zhang

Published in: Journal of Ovarian Research | Issue 1/2014

Abstract

Background

Dexamethasone (DEX) has been routinely used as a pre-treatment in the clinical application of paclitaxel (PTX) to treat ovarian cancer. However, PTX-induced apoptosis might be inhibited by DEX. This study was undertaken to investigate the effects of DEX on the apoptosis induced by PTX.

Methods

Both of SKOV-3 and HO-8910 human ovarian cancer cells were divided into four groups: (1) untreated (Con); (2) treated with DEX (0.1 μM) alone; (3) treated with PTX (50 nM); and (4) pre-treated with DEX (0.1 μM), and 24 h later, treated with PTX (DEX + PTX). Cell proliferation was determined by the 3-(4,5)-dimethylthiahiazo (−z-y1)-3,5-di- phenytetrazoliumromide (MTT) dye uptake method, while cell apoptosis was analyzed by propidium iodide (PI) staining and flow cytometry. Then, reverse transcription polymerase chain reactions (RT-PCRs) were applied to semi-quantitative analysis, followed by western blot analysis. Statistical analysis was performed, with Fisher’s least significant difference test.

Results

Our results demonstrated that DEX can differentially inhibit SKOV-3 and HO-8910 cell proliferation induced by PTX and decrease the apoptosis rates in cancer cells. Pre-treatment with DEX could up-regulate the expressions of members of anti-apoptotic Bcl-2 family (Bcl-2 and Bcl-XL) and members of IAP family (survivin). The expression of cleaved caspase-3 was down-regulated by DEX, shown by semi-quantitative RT-PCRs and western blot analysis.

Conclusions

Our data gained invaluable insights of the antagonistic mechanisms of DEX on PTX-induced cancer cell death and may provide new methods of using DEX as antineoplastic drugs or agents in the clinical treatment for ovarian cancer patients.

Available only for authorised users

Hippisley-Cox J, Coupland C: Identifying women with suspected ovarian cancer in primary care: derivation and validation of algorithm. Br Med J 2012, 4: 344.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62: 220–241. 10.3322/caac.21149CrossRefPubMed

Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH: A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003, 88: 130–135. 10.1016/S0090-8258(02)00091-4CrossRefPubMed

Lorusso V, Giampaglia M, Petrucelli L, Saracino V, Perrone T, Gnoni A: Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy. Support Care Cancer 2012, 20: 3241–3246. 10.1007/s00520-012-1469-9PubMedCentralCrossRefPubMed

Zhang Q, Huang XE, Gao LL: A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother 2009, 63: 603–607. 10.1016/j.biopha.2008.10.001CrossRefPubMed

Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D: Premedication strategy for weekly paclitaxel. Cancer Invest 2002, 20: 666–672. 10.1081/CNV-120003535CrossRefPubMed

Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM: Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 2003, 63: 3112–3120.PubMed

Sui M, Chen F, Chen Z, Fan W: Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 2006, 119: 712–717. 10.1002/ijc.21743CrossRefPubMed

Zhang C, Beckermann B, Kallifatidis G, Liu Z, Rittgen W, Edler L, Buchler P, Debatin KM, Buchler MW, Friess H, Herr I: Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int J Oncol 2006, 29: 1295–1301.PubMed

10.

Zhang C, Kolb A, Buchler P, Cato AC, Mattern J, Rittgen W, Edler L, Debatin KM, Buchler MW, Friess H, Herr I: Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. BMC Cancer 2006, 6: 61. 10.1186/1471-2407-6-61PubMedCentralCrossRefPubMed

11.

Zhang C, Kolb A, Mattern J, Gassler N, Wenger T, Herzer K, Debatin KM, Buchler M, Friess H, Rittgen W, Edler L, Herr I: Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Lett 2006, 242: 104–111. 10.1016/j.canlet.2005.10.037CrossRefPubMed

12.

Zhang C, Marme A, Wenger T, Gutwein P, Edler L, Rittgen W, Debatin KM, Altevogt P, Mattern J, Herr I: Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int J Oncol 2006, 28: 551–558.PubMed

13.

Zhang C, Mattern J, Haferkamp A, Pfitzenmaier J, Hohenfellner M, Rittgen W, Edler L, Debatin KM, Groene E, Herr I: Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther 2006, 5: 59–64. 10.4161/cbt.5.1.2272CrossRefPubMed

14.

Gassler N, Zhang C, Wenger T, Schnabel PA, Dienemann H, Debatin KM, Mattern J, Herr I: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. Br J Cancer 2005, 92: 1084–1088. 10.1038/sj.bjc.6602453PubMedCentralCrossRefPubMed

15.

Rutz HP: Effects of corticosteroid use on treatment of solid tumours. Lancet 2002, 360: 1969–1970. 10.1016/S0140-6736(02)11922-2CrossRefPubMed

16.

Rutz HP, Herr I: Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther 2004, 3: 715–718. 10.4161/cbt.3.8.966CrossRefPubMed

17.

Hengartner MO: The biochemistry of apoptosis. Nature 2000, 407: 770–776. 10.1038/35037710CrossRefPubMed

18.

Herr I, Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98: 2603–2614. 10.1182/blood.V98.9.2603CrossRefPubMed

19.

Krammer PH: CD95’s deadly mission in the immune system. Nature 2000, 407: 789–795. 10.1038/35037728CrossRefPubMed

20.

Das A, Banik NL, Patel SJ, Ray SK: Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol Cancer 2004, 3: 36. 10.1186/1476-4598-3-36PubMedCentralCrossRefPubMed

21.

Gorman AM, Hirt UA, Orrenius S, Ceccatelli S: Dexamethasone pre-treatment interferes with apoptotic death in glioma cells. Neuroscience 2000, 96: 417–425. 10.1016/S0306-4522(99)00565-5CrossRefPubMed

22.

Ni Chonghaile T, Concannon CG, Szegezdi E, Gorman AM, Samali A: Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL. Apoptosis 2006, 11: 1247–1255. 10.1007/s10495-006-7233-1CrossRefPubMed

23.

Cuevas P, Diaz-Gonzalez D, Sanchez I, Lozano RM, Gimenez-Gallego G, Dujovny M: Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells. Neurol Res 2006, 28: 127–130. 10.1179/016164106X97982CrossRefPubMed

24.

de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L: STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000, 3: 299–305. 10.1006/mcbr.2000.0231CrossRefPubMed

25.

Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21: 8404–8413. 10.1038/sj.onc.1206047CrossRefPubMed

26.

Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R: Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004,11(Suppl 1):S45-S55. 10.1038/sj.cdd.4401456CrossRefPubMed

27.

Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD: Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004, 64: 1757–1764. 10.1158/0008-5472.CAN-03-2546CrossRefPubMed

28.

Wu W, Pew T, Zou M, Pang D, Conzen SD: Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J Biol Chem 2005, 280: 4117–4124. 10.1074/jbc.M411200200CrossRefPubMed

29.

Brenes O, Arce F, Gatjens-Boniche O, Diaz C: Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance. Biomed Pharmacother 2007, 61: 347–355. 10.1016/j.biopha.2007.02.007CrossRefPubMed

30.

Morita M, Suyama H, Igishi T, Shigeoka Y, Kodani M, Hashimoto K, Takeda K, Sumikawa T, Shimizu E: Dexamethasone inhibits paclitaxel-induced cytotoxic activity through retinoblastoma protein dephosphorylation in non-small cell lung cancer cells. Int J Oncol 2007, 30: 187–192.PubMed

31.

Chen DW, Lynch JT, Demonacos C, Krstic-Demonacos M, Schwartz JM: Quantitative analysis and modeling of glucocorticoid-controlled gene expression. Pharmacogenomics 2010, 11: 1545–1560. 10.2217/pgs.10.125CrossRefPubMed

32.

Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, Altevogt P, Bodenmuller W, Gassler N, Schnabel PA, Dienemann H, Marmé A, Hohenfellner M, Haferkamp A, Pfitzenmaier J, Gröne HJ, Kolb A, Büchler P, Büchler M, Friess H, Rittgen W, Edler L, Debatin KM, Krammer PH, Rutz HP, Herr I: Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 2007, 6: 278–287. 10.4161/cbt.6.2.3652CrossRefPubMed

33.

Gascoyne DM, Kypta RM, Vivanco M: Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL. J Biol Chem 2003, 278: 18022–18029. 10.1074/jbc.M301812200CrossRefPubMed

34.

Wada T, Pippin JW, Marshall CB, Griffin SV, Shankland SJ: Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol 2005, 16: 2615–2625. 10.1681/ASN.2005020142CrossRefPubMed

35.

Wanke I, Schwarz M, Buchmann A: Insulin and dexamethasone inhibit TGF-beta-induced apoptosis of hepatoma cells upstream of the caspase activation cascade. Toxicology 2004, 204: 141–154. 10.1016/j.tox.2004.06.020CrossRefPubMed

36.

Machuca C, Mendoza-Milla C, Cordova E, Mejia S, Covarrubias L, Ventura J, Zentella A: Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells requires NF-kappaB and is independent from AKT. BMC Cell Biol 2006, 7: 9. 10.1186/1471-2121-7-9PubMedCentralCrossRefPubMed

37.

Fan W, Sui M, Huang Y: Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: mechanisms and its clinical impact. Curr Med Chem 2004, 11: 403–411. 10.2174/0929867043455990CrossRefPubMed

38.

Huang Y, Johnson KR, Norris JS, Fan W: Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000, 60: 4426–4432.PubMed

39.

Chen YX, Wang Y, Fu CC, Diao F, Song LN, Li ZB, Yang R, Lu J: Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr Relat Cancer 2010, 17: 39–50. 10.1677/ERC-08-0296CrossRefPubMed

40.

Huang Y, Fan W: IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 2002, 61: 105–113. 10.1124/mol.61.1.105CrossRefPubMed

41.

Huang Y, Fang Y, Dziadyk JM, Norris JS, Fan W: The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis. Oncol Res 2002, 13: 113–122.PubMed

42.

Yang N, Zhang H, Si-Ma H, Fu Y, Zhao W, Li D, Yang G: Dexamethasone decreases hepatocellular carcinoma cell sensitivity to cisplatin-induced apoptosis. Hepatogastroenterology 2011, 58: 1730–1735. 10.5754/hge11153CrossRefPubMed

43.

Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O’Shea JJ, Chrousos GP, Bornstein SR: Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. Faseb J 2002, 16: 61–71. 10.1096/fj.01-0245comCrossRefPubMed

44.

Igney FH, Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002, 2: 277–288. 10.1038/nrc776CrossRefPubMed

45.

Kaufmann SH, Hengartner MO: Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001, 11: 526–534. 10.1016/S0962-8924(01)02173-0CrossRefPubMed

46.

Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002, 2: 420–430. 10.1038/nrc821CrossRefPubMed

47.

Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC: Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002, 21: 1346–1358. 10.1038/sj.onc.1205205CrossRefPubMed

48.

Liu Q, Gazitt Y: Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells. Blood 2003, 101: 4105–4114. 10.1182/blood-2002-10-3067CrossRefPubMed

49.

Schmidt M, Lugering N, Lugering A, Pauels HG, Schulze-Osthoff K, Domschke W, Kucharzik T: Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J Immunol 2001, 166: 1344–1351. 10.4049/jimmunol.166.2.1344CrossRefPubMed

50.

Croxtall JD, Choudhury Q, Flower RJ: Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000, 130: 289–298. 10.1038/sj.bjp.0703272PubMedCentralCrossRefPubMed

Title: RETRACTED ARTICLE: The effects of dexamethasone on the proliferation and apoptosis of human ovarian cancer cells induced by paclitaxel
Authors: Wenjing Hou
Jianhua Guan
Huan Lu
Qian Dong
Yuhong Han
Rong Zhang
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2014
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-014-0089-z

At a glance: The STEP trials

Springer Medicine

RETRACTED ARTICLE: The effects of dexamethasone on the proliferation and apoptosis of human ovarian cancer cells induced by paclitaxel

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Epicardial adipose tissue thickness and NGAL levels in women with polycystic ovary syndrome

Plasma concentrations of D-dimer and outcome of in vitro fertilization

Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3

Low dose of rFSH [100 IU] in controlled ovarian hyperstimulation response: a pilot study

Urinary interleukin-1β levels among gynecological patients

Luteal activity of pregnant rats with hypo-and hyperthyroidism